Literature DB >> 28701441

Topiramate for pediatric migraine prevention.

Teeranai Sakulchit, Garth D Meckler, Ran D Goldman.   

Abstract

Question I have several teenagers in my clinic with migraine headache and some of them have frequent episodes that cause considerable interference with daily activity. I would like to offer them prophylactic therapy to reduce the frequency of their migraine episodes. Is topiramate an effective and safe option for adolescents? Answer Both Health Canada and the US Food and Drug Administration have approved the use of topiramate for migraine prevention in adults; however, only the US Food and Drug Administration has approved topiramate for migraine prophylaxis in adolescents 12 to 17 years of age. Although several studies support its effectiveness in preventing migraine, most of these studies are small; and a recent large multicentre, randomized placebo-controlled trial was stopped early when no benefit was shown over placebo. Adverse effects of topiramate are mild and typically resolve over time. The recommended dosage is 2 mg/kg per day, up to an adult dose of 100 mg/d. Copyright© the College of Family Physicians of Canada.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28701441      PMCID: PMC5507226     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  21 in total

Review 1.  Topiramate for migraine prophylaxis in pediatric patients.

Authors:  Tamara L Deaton; Laurie S Mauro
Journal:  Ann Pharmacother       Date:  2014-02-24       Impact factor: 3.154

2.  Efficacy and tolerability of topiramate in pediatric migraine.

Authors:  Marcos J Cruz; Ignacio Valencia; Agustín Legido; Sanjeev V Kothare; Divya S Khurana; Sabrina Yum; Huntley H Hardison; Joseph J Melvin; Harold G Marks
Journal:  Pediatr Neurol       Date:  2009-09       Impact factor: 3.372

3.  Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial.

Authors:  C V S Lakshmi; Pratibha Singhi; Prahbhjot Malhi; Munni Ray
Journal:  J Child Neurol       Date:  2007-07       Impact factor: 1.987

Review 4.  Epidemiology of migraine and headache in children and adolescents.

Authors:  Ciçek Wöber-Bingöl
Journal:  Curr Pain Headache Rep       Date:  2013-06

Review 5.  Drugs for the acute treatment of migraine in children and adolescents.

Authors:  Lawrence Richer; Lori Billinghurst; Meghan A Linsdell; Kelly Russell; Ben Vandermeer; Ellen T Crumley; Tamara Durec; Terry P Klassen; Lisa Hartling
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19

Review 6.  Pediatric migraine: pharmacologic agents for prophylaxis.

Authors:  Lea S Eiland; Lauren S Jenkins; Spencer H Durham
Journal:  Ann Pharmacother       Date:  2007-06-05       Impact factor: 3.154

7.  Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age.

Authors:  Donald Lewis; Paul Winner; Joel Saper; Seth Ness; Elena Polverejan; Steven Wang; Caryn L Kurland; Jeff Nye; Eric Yuen; Marielle Eerdekens; Lisa Ford
Journal:  Pediatrics       Date:  2009-03       Impact factor: 7.124

8.  Effective dose of topiramate in pediatric migraine prophylaxis.

Authors:  Ali Abbaskhanian; Hamid Reza Sadeghi; Ali Erfani; Mohammad Sadegh Rezai
Journal:  J Pediatr Neurosci       Date:  2012-09

9.  The efficacy and safety of topiramate for prophylaxis of migraine in children.

Authors:  Razieh Fallah; Sedighah Akhavan Karbasi; Ahmad Shajari; Mostafa Fromandi
Journal:  Iran J Child Neurol       Date:  2013

10.  Prophylaxis of childhood migraine: topiramate versus propranolol.

Authors:  Seyed Hassan Tonekaboni; Ahad Ghazavi; Afshin Fayyazi; Ali Khajeh; Mohammad Mahdi Taghdiri; Fatemeh Abdollah Gorji; Eznollah Azarghashb
Journal:  Iran J Child Neurol       Date:  2013
View more
  2 in total

1.  Outcomes of topiramate for prophylaxis of chronic migraine headache.

Authors:  Khawar Ahmed; Hussain Rafiq; Shalmeen Tariq
Journal:  Pak J Med Sci       Date:  2022 Jul-Aug       Impact factor: 2.340

Review 2.  Management of Chronic Migraine in Children and Adolescents: Where are We in 2022?

Authors:  Robert C Gibler; Kaelynn E Knestrick; Brooke L Reidy; Daniel N Lax; Scott W Powers
Journal:  Pediatric Health Med Ther       Date:  2022-09-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.